GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Cash Flow from Financing

Diamyd Medical AB (OSTO:DMYD B) Cash Flow from Financing : kr119.04 Mil (TTM As of Feb. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Feb. 2025, Diamyd Medical AB paid kr0.00 Mil more to buy back shares than it received from issuing new shares. It received kr0.00 Mil from issuing more debt. It paid kr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received kr0.00 Mil from paying cash dividends to shareholders. It received kr0.00 Mil on other financial activities. In all, Diamyd Medical AB spent kr0.00 Mil on financial activities for the three months ended in Feb. 2025.


Diamyd Medical AB Cash Flow from Financing Historical Data

The historical data trend for Diamyd Medical AB's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Cash Flow from Financing Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 56.72 142.16 86.54 142.28

Diamyd Medical AB Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.21 61.44 -0.84 59.07 -0.64

Diamyd Medical AB Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Diamyd Medical AB's Cash from Financing for the fiscal year that ended in Aug. 2024 is calculated as:

Diamyd Medical AB's Cash from Financing for the quarter that ended in Feb. 2025 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr119.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diamyd Medical AB  (OSTO:DMYD B) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Diamyd Medical AB's issuance of stock for the three months ended in Feb. 2025 was kr0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Diamyd Medical AB's repurchase of stock for the three months ended in Feb. 2025 was kr0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Diamyd Medical AB's net issuance of debt for the three months ended in Feb. 2025 was kr0.00 Mil. Diamyd Medical AB received kr0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Diamyd Medical AB's net issuance of preferred for the three months ended in Feb. 2025 was kr0.00 Mil. Diamyd Medical AB paid kr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Diamyd Medical AB's cash flow for dividends for the three months ended in Feb. 2025 was kr0.00 Mil. Diamyd Medical AB received kr0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Diamyd Medical AB's other financing for the three months ended in Feb. 2025 was kr0.00 Mil. Diamyd Medical AB received kr0.00 Mil on other financial activities.


Diamyd Medical AB Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines